; and (ii) the wholesale acquisition cost of each such drug. (B) Administrative fee The Secretary may pay a manufacturer an administrative fee pursuant to an agreement under this section, provided that the payment of the administrative fee does not cause the Secretary to exhaust the amounts appropriated for the pilot program under this section prior to securing adequate reserves for each covered pediatric cancer drug. (2) Payment conditioned on reserve supply adequacy (A) In general Except as provided in subparagraph (B), each agreement with a manufacturer under this section shall provide that no payment under the agreement may be made until the manufacturer demonstrates to the Secretary that the manufacturer has set aside a portion, as determined by the Secretary, of the total quantity of the covered pediatric cancer drug to be held in reserve supply under the agreement. (B) Exceptions for advance payment An agreement under this section may provide that, if the Secretary determines that an advance payment or partial payment for significant milestones is necessary to ensure success of the terms of the agreement, the Secretary shall pay, in advance, an amount not to exceed 10 percent of the total amount to be paid to the manufacturer by the Secretary under the agreement. (d) Forfeiture If a manufacturer is unable or fails to distribute a covered pediatric cancer drug in accordance with the terms of an agreement entered into under this section, the manufacturer shall— (1) forfeit any payments it has received under the agreement; and (2) not later than 30 days after the date of such inability or failure, refund such payments. 3. Essential pediatric cancer drug list (a) In general The Secretary, in consultation with the Commissioner of Food and Drugs and the Director of the National Cancer Institute, shall— (1) not later than 150 days after the date of enactment of this Act, develop a list of chemotherapeutic drugs that are essential for treating pediatric cancer